Larimar Therapeutics
LRMR3.7403.03% ( +0.110 )
Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Preview: Larimar Therapeutics(LRMR) predict that the EBIT is -31.12 M (+0.23%), Beat estimate;the EPS is -0.31 (+32.61%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.03B0.23%
-0.05B66.46%
+0.02B66.69%
EPSExceed expectations
-0.3132.61%
-0.535716.46%
+0.225749.07%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf